The publishers of JHOP and TON are pleased to present an exclusive podcast providing peer-to-peer nursing perspectives on the current role of immunotherapy in patients with advanced multiple myeloma (MM) and introducing a new class of agents: T-cell–redirecting bispecific antibodies (Tcr-bsAbs).

Topics include:

• Key features of teclistamab, an investigational Tcr-bsAb
• Importance of treating clinicians to reliably identify adverse events (AEs) that may occur with this class of drugs, eg, cytokine release syndrome, and optimal strategies for educating patients and their caregivers on these AEs
• The role of oncology nurses in conveying the potential value of innovative immunotherapies such as teclistamab to candidate patients, while setting realistic expectations regarding treatment outcomes
• Key insights into the transition of care and personal journey of patients with multi-refractory MM who will be receiving therapy with Tcr-bsAbs

Multi-Refractory MM: Supporting the Patient Receiving a Novel T-Cell–Redirecting Bispecific Antibody

Panelists